Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/38497
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zipprich, Alexander | - |
dc.contributor.author | Gittinger, Fleur Sophie | - |
dc.contributor.author | Winker, Matthias | - |
dc.contributor.author | Dollinger, Matthias | - |
dc.contributor.author | Ripoll, Cristina | - |
dc.date.accessioned | 2021-09-27T13:43:55Z | - |
dc.date.available | 2021-09-27T13:43:55Z | - |
dc.date.issued | 2021 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/38743 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/38497 | - |
dc.description.abstract | Background/aim: Endothelin causes vasoconstriction via the endothelin-A receptor (ET-A) in the intrahepatic circulation in cirrhosis and its increase leads to portal hypertension. The aim of the study was to investigate the acute effect of a selective ET-A antagonist in patients with portal hypertension and cirrhosis. Methods: Proof-of-concept study with two different substudies: (a) local intrahepatic administration of the ET-A antagonist BQ 123 and (b) systemic oral administration of the ET-A antagonist Ambrisentan. Portal pressure was determined by hepatic venous pressure gradient (HVPG, both substudies) and hepatic arterial blood flow (HABF) by intra-arterial Doppler measurements (substudy 1) before and under the ET-A antagonist. Systemic haemodynamic parameters were measured in substudy 2. Results: Twelve patients (Child-Pugh [CP] B/C n = 7/5) were included in substudy 1 and 14 patients (CP A/B/C n = 4/6/4) in substudy 2. The relative decrease in HVPG was −12.5% (IQR: −40% to 0%; P = .05) in substudy 1 and −5.0% (IQR: −11.5% to 0%; P = .01) in substudy 2. Substudy 1 revealed higher decrease in HVPG in CP B patients. HABF increased significantly and patients without portal pressure decrease showed a higher increase of HABF. Substudy 2 showed a slight decrease in the mean arterial pressure without changes of other systemic haemodynamic parameters. Conclusion: Administration of a selective ET-A antagonist decreases the portal pressure in cirrhotic patients. This decrease was higher in CP B patients and the non-responders showed a higher increase in hepatic arterial flow. Selective ET-A antagonists might be a future treatment option in patients with portal hypertension. | eng |
dc.description.sponsorship | Publikationsfond MLU | - |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.subject.ddc | 616 | - |
dc.title | Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis : a proof of concept study | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Liver international | - |
local.bibliographicCitation.volume | 41 | - |
local.bibliographicCitation.issue | 3 | - |
local.bibliographicCitation.pagestart | 554 | - |
local.bibliographicCitation.pageend | 561 | - |
local.bibliographicCitation.publishername | Wiley-Blackwell | - |
local.bibliographicCitation.publisherplace | Oxford | - |
local.bibliographicCitation.doi | 10.1111/liv.14757 | - |
local.subject.keywords | cirrhosis, endothelin, haemodynamics, hepatic venous pressure gradient | - |
local.openaccess | true | - |
dc.identifier.ppn | 1753200296 | - |
local.bibliographicCitation.year | 2021 | - |
cbs.sru.importDate | 2021-09-27T13:40:28Z | - |
local.bibliographicCitation | Enthalten in Liver international - Oxford : Wiley-Blackwell, 2003 | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
liv.14757.pdf | 496.33 kB | Adobe PDF | View/Open |